BGMS · Bio Green Med Solution, Inc. · Investor Relations
Substantial doubt about the company's ability to continue as a going concern.
“Our history of losses, our negative cash flows from operations, our liquidity resources currently on hand, and our dependence on the ability to obtain additional financing to fund our operations after the current resources are exhausted, about which there can be no certainty, have resulted in our assessment that there is substantial doubt about our ability to continue as a going concern for a period of at least twelve months from the issuance date of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 14, 2026
4 customers — 55% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
One customer — 36% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
One customer — 7% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
One customer — 6% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
One customer — 6% of revenue (the December 31, 2025 financial year)
“In the December 31, 2025 financial year, our top four customers collectively accounted for 55% of the Company's total sales, with individual contributions of approximately 36%, 7%, 6%, and 6%, respectively.”
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2024-09-09 | H.C. Wainwright 26th Annual Global Investment Conference | Conference |
| 2024-08-14 | Second Quarter 2024 Earnings | Earnings call |
| 2024-06-01 | Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer | Shareholder meeting |
Source: https://bgmsglobal.com/investors